ELAVL1 and cancer: This discrepancy likely stems from the following: (i) methodological differences (subtype-stratified IHC vs. pan-cancer mRNA sequencing) and (ii) post-transcriptional regulation by ELAVL1, which stabilizes CELF1 protein in aggressive subtypes, as observed in oral SCCs (House et al., 2015).